Skip to main content
. 2020 Sep 1;4:24. doi: 10.1038/s41698-020-00129-0

Fig. 3. Engineering melittin with an RGD motif enhances breast cancer selectivity.

Fig. 3

a Cell-viability assays of TNBC (SUM159) and HER2-enriched breast cancer (SKBR3) cells treated with DEDE-melittin for 24 h. b Cell-viability assays of T11 cells treated with melittin, RGD1-melittin, SV40-melittin, and DEDE-melittin for 24 h (t test). c Cell-viability assays of normal human dermal fibroblasts (HDFa) and SUM159 treated with melittin (left) and RGD1-melittin (right) for 24 h (t tests). d Western blot for the detection of cleaved caspase-3 (CL-csp-3) in lysates from SUM159 cells treated with vehicle, melittin, DEDE-melittin, or RGD1-melittin for 24 h. e Absorbance (405 nm) of aqueous solutions of melittin, RGD1-melittin, DEDE-melittin, and SV40-melittin subjected to an ELISA with the anti-melittin antibody (two-way ANOVA). f The amino-acid sequence and top predicted 3D model of melittin (green), RGD1-melittin (purple), DEDE-melittin (blue), and SV40-melittin (orange). g Immunofluorescence images of SUM159 treated with vehicle, honeybee venom, melittin, RGD1-melittin, or DEDE-melittin for 30 min. In blue: cell nuclei, in red: anti-EGFR, and in green: anti-melittin. The white outlines in the merged images indicate the respective regions in the zoomed images. Scale bars represent 25 µm, and 6.25 µm for the zoomed images. Data are represented as mean ± SEM (n = 3). Differences were considered significant at p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***). See also Supplementary Figs. 3 and 10.